Literature DB >> 18060551

Mechanisms of neurodegeneration in mucopolysaccharidoses II and IIIB: analysis of human brain tissue.

Kimiko Hamano1, Masaharu Hayashi, Kei Shioda, Ryo Fukatsu, Shuki Mizutani.   

Abstract

Mucopolysaccharidoses (MPS) are inherited disorders caused by the deficiency of lysosomal enzymes. Sanfilippo syndrome (MPS III) and Hunter syndrome (MPS II) are characterized by severe and mild neurological disorders, respectively, in which the neurodegenerative mechanisms remain to be clarified. We immunohistochemically examined the involvement of tauopathy/synucleinopathy, cell death and oxidative damage in the brains of three cases each of MPS IIIB and MPS II and age-matched controls. In cases of MPS IIIB, the density of GABAergic interneurons in the cerebral cortex immunoreactive for calbindin-D28K and parvalbumin was markedly reduced when compared with age-matched controls. The swollen neurons showed immunoreactivity for phosphorylated alpha-synuclein but not for phosphorylated tau protein or beta-amyloid protein; those in the cerebral cortex demonstrated nuclear immunoreactivity for TUNEL, single-stranded DNA and 8-OHdG. Neither lipid peroxidation nor protein glycation was marked in MPS cases. The expression levels of superoxide dismutases (Cu/ZnSOD and MnSOD) and glial glutamate transporters (EAAT1 and EAAT2) were reduced in two MPS II cases. The disturbance of GABAergic interneurons can be related to mental disturbance, while synucleinopathy and/or DNA impairment may be implicated in the neurodegeneration of swelling neurons due to storage materials in MPS IIIB cases. These findings suggest the possibility of neuroprotective therapies other than enzyme replacement in MPS patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18060551     DOI: 10.1007/s00401-007-0325-3

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  39 in total

1.  Near-Complete Correction of Profound Metabolomic Impairments Corresponding to Functional Benefit in MPS IIIB Mice after IV rAAV9-hNAGLU Gene Delivery.

Authors:  Haiyan Fu; Aaron S Meadows; Tierra Ware; Robert P Mohney; Douglas M McCarty
Journal:  Mol Ther       Date:  2017-01-28       Impact factor: 11.454

2.  Neuroinflammation, mitochondrial defects and neurodegeneration in mucopolysaccharidosis III type C mouse model.

Authors:  Carla Martins; Helena Hůlková; Larbi Dridi; Virginie Dormoy-Raclet; Lubov Grigoryeva; Yoo Choi; Alexander Langford-Smith; Fiona L Wilkinson; Kazuhiro Ohmi; Graziella DiCristo; Edith Hamel; Jerôme Ausseil; David Cheillan; Alain Moreau; Eva Svobodová; Zuzana Hájková; Markéta Tesařová; Hana Hansíková; Brian W Bigger; Martin Hrebícek; Alexey V Pshezhetsky
Journal:  Brain       Date:  2015-01-06       Impact factor: 13.501

3.  Lessons learnt from animal models: pathophysiology of neuropathic lysosomal storage disorders.

Authors:  Kim M Hemsley; John J Hopwood
Journal:  J Inherit Metab Dis       Date:  2010-05-07       Impact factor: 4.982

Review 4.  Cell- and gene-based therapeutic approaches for neurological deficits in mucopolysaccharidoses.

Authors:  Dao Pan
Journal:  Curr Pharm Biotechnol       Date:  2011-06       Impact factor: 2.837

5.  Glycosaminoglycan storage in neuroanatomical regions of mucopolysaccharidosis I dogs following intrathecal recombinant human iduronidase.

Authors:  Agnes Chen; Carole Vogler; Michael McEntee; Stephen Hanson; N Matthew Ellinwood; Jackie Jens; Elizabeth Snella; Merry Passage; Steven Le; Catalina Guerra; Patricia Dickson
Journal:  APMIS       Date:  2011-05-14       Impact factor: 3.205

6.  The efficacy of intracerebroventricular idursulfase-beta enzyme replacement therapy in mucopolysaccharidosis II murine model: heparan sulfate in cerebrospinal fluid as a clinical biomarker of neuropathology.

Authors:  Young Bae Sohn; Ah-Ra Ko; Mi-Ran Seong; Soyeon Lee; Mi Ra Kim; Sung Yoon Cho; Jung-Sun Kim; Makoto Sakaguchi; Takahiro Nakazawa; Motomichi Kosuga; Joo Hyun Seo; Torayuki Okuyama; Dong-Kyu Jin
Journal:  J Inherit Metab Dis       Date:  2018-07-05       Impact factor: 4.982

7.  Quantitative in vivo brain magnetic resonance spectroscopic monitoring of neurological involvement in mucopolysaccharidosis type II (Hunter Syndrome).

Authors:  James E Davison; Christian J Hendriksz; Yu Sun; Nigel P Davies; Paul Gissen; Andrew C Peet
Journal:  J Inherit Metab Dis       Date:  2010-10-01       Impact factor: 4.982

8.  CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome).

Authors:  Sandra Motas; Virginia Haurigot; Miguel Garcia; Sara Marcó; Albert Ribera; Carles Roca; Xavier Sánchez; Víctor Sánchez; Maria Molas; Joan Bertolin; Luca Maggioni; Xavier León; Jesús Ruberte; Fatima Bosch
Journal:  JCI Insight       Date:  2016-06-16

9.  Serum global metabolomics profiling reveals profound metabolic impairments in patients with MPS IIIA and MPS IIIB.

Authors:  Haiyan Fu; Aaron S Meadows; Ricardo J Pineda; Robert P Mohney; Steve Stirdivant; Douglas M McCarty
Journal:  Metab Brain Dis       Date:  2017-04-05       Impact factor: 3.584

10.  Blood genome-wide transcriptional profiles reflect broad molecular impairments and strong blood-brain links in Alzheimer's disease.

Authors:  Bartholomew J Naughton; F Jason Duncan; Darren A Murrey; Aaron S Meadows; David E Newsom; Nicoleta Stoicea; Peter White; Douglas W Scharre; Douglas M Mccarty; Haiyan Fu
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.